Market Place
Sourcing Support
Celltrion Presents Phase III Data for CT-41 & CT-P47 Biosimilars
18 Nov 2024 //
PR NEWSWIRE
CMS Grants Fresenius Kabi Q-Code and Payment Status for Tyenne®
29 Oct 2024 //
BUSINESSWIRE
Genentech`s Biologic Actemra(Tocilizumab) Receives Suppl Approval in US
19 Sep 2024 //
FDA
Bio-Thera And Biogen Publish TOFIDENCE Phase 3 Trial Data
11 Sep 2024 //
PR NEWSWIRE
Fresenius Launches Subcutaneous Tyenne In US Market
02 Jul 2024 //
BUSINESSWIRE
TOFIDENCE™ (tocilizumab) Biosimilar Approved in the European Union
24 Jun 2024 //
GLOBENEWSWIRE
Biogen`s Tofidence (tocilizumab) Receives Approval in Europe
20 Jun 2024 //
EMA
Celltrion showcases promising results in phase III study for CT-P47
13 Jun 2024 //
BUSINESSWIRE
Biogen`s TOFIDENCE Biosimilar Referencing ROACTEMRA Gets CHMP Opinion
25 Apr 2024 //
GLOBENEWSWIRE
Fresenius Momentum In (Bio)Pharma, Launches Tyenne® Biosimilar
15 Apr 2024 //
BUSINESSWIRE
Celltrion USA completes submission of Biologics License Application for CT-P47
28 Jan 2024 //
PR NEWSWIRE
Roche settles US patent lawsuit against Biogen over blockbuster arthritis drug
24 Oct 2023 //
REUTERS
FDA Approves TOFIDENCE™ (tocilizumab-bavi) a Biosimilar of ACTEMRA
08 Oct 2023 //
PR NEWSWIRE
Fresenius Kabi`s Tyenne (tocilizumab) Receives Approval in Europe
02 Oct 2023 //
EMA
FDA Approves Biogen’s TOFIDENCE, a Biosimilar Referencing ACTEMRA
30 Sep 2023 //
GLOBENEWSWIRE
Tyenne, Fresenius Kabi’s tocilizumab biosimilar, receives EC approval
20 Sep 2023 //
PRESS RELEASE
Roche sues Biogen over biosimilar of blockbuster arthritis drug
15 Jul 2023 //
NASDAQ
Dr. Reddy’s Successfully Completes Phase I Study (IV Route) of DRL_TC
05 Jun 2023 //
BUSINESSWIRE
Trio of COVID-19 treatments receive NICE nod
21 Feb 2023 //
PHARMATIMES
China NMPA Approves Bio-Thera’s BAT1806, A Biosimilar to Actemra® (Tocilizumab)
16 Jan 2023 //
BUSINESSWIRE
New monoclonal antibody for hospitalised COVID-19 patients approved by FDA
23 Dec 2022 //
PHARMAFILE
FDA approves Roche’s Actemra for the treatment of COVID-19 hospitalised adults
22 Dec 2022 //
GLOBENEWSWIRE
Genentech` Biologic Actemra (Tocilizumab) Receives Approval in the U.S.
21 Dec 2022 //
FDA
FDA Approves Genentech’s Actemra for COVID-19 in Hospitalized Adults
21 Dec 2022 //
BUSINESSWIRE
Dr Reddy`s Lab completes Phase 1 study of proposed arthritis drug
19 Dec 2022 //
ECONOMIC TIMES
Dr Reddy`s Lab completes Phase 1 study of proposed arthritis drug
19 Dec 2022 //
ECONOMIC TIMES
FDA Accepts Biogen Biologics License Application for BIIB800
09 Dec 2022 //
GLOBENEWSWIRE
Roche to supply Actemra IV courses to Canada for Covid-19
02 Dec 2022 //
PHARMACEUTICAL-TECHNOLOGY
Roche’s Actemra gets Health Canada approval for Covid-19 treatment
31 Oct 2022 //
PHARMACEUTICAL-TECHNOLOGY
Biogen Announced EMA Filing Acceptance of BIIB800
30 Sep 2022 //
GLOBENEWSWIRE
Celltrion`s CT-P47 approved for Phase 3 trials in Poland
19 Jul 2022 //
KOREA DAILY
Biogen and Bio-Thera Present PIII Data for Tocilizumab Biosimilar Candidate
03 Jun 2022 //
GLOBENEWSWIRE
Celltrion sends trial plans for global P3 study for Actemra biosimilar
17 May 2022 //
KOREABIOMED
U.S. FDA Grants Priority Review to Genentech’s Actemra for COVID-19
04 Apr 2022 //
BUSINESSWIRE
Genentech`s Biologic Actemra (Tocilizumab) Receives Approval in the U.S.
28 Feb 2022 //
FDA
Roche’s Actemra/RoActemra obtains WHO prequalification to treat Covid-19
14 Feb 2022 //
PHARMACEUTICAL-TECHNOLOGY
WHO prequalifies first monoclonal antibody - tocilizumab – to treat COVID-19
11 Feb 2022 //
WHO
CalciMedica Initiates CARDEA-Plus Trial of Auxora in COVID-19 Pneumonia
20 Jan 2022 //
PRNEWSWIRE
DCGI raises alarm over suspected spurious tocilizumab injections in India
11 Jan 2022 //
PHARMABIZ
Limited availability of RoActemra (Roche): new situation update
23 Dec 2021 //
FAMHP
Theramex, Enzene Partner for the Development & Commercialisation of Tocilizumab
23 Dec 2021 //
BUSINESSWIRE
Limited availability of RoActemra (Roche): new situation update
23 Dec 2021 //
FAMHP
Theramex, Enzene Partner for the Development & Commercialisation of Tocilizumab
23 Dec 2021 //
BUSINESSWIRE
Genentech`s tocilizumab shortage due to Covid-19 now hits CAR-T recipients
13 Dec 2021 //
ENDPTS
EMA recommends RoActemra in adults with severe COVID-19
10 Dec 2021 //
EUROPEANPHARMACEUTICALREVIEW
EC extends marketing authorisation for tocilizumabto in severe Covid
08 Dec 2021 //
PHARMABIZ
Actemra/RoActemra approved by the European Commission to treat patients
07 Dec 2021 //
GLOBENEWSWIRE
EMA Expands Authorization for Roche’s Actemra/RoActemra in COVID
07 Dec 2021 //
CONTRACTPHARMA
TGA Provisional Approval of Roche Products COVID-19 treatment, tocilizumab
01 Dec 2021 //
TGA
Genentech`s Actemra (tocilizumab) Receives Supplemental Approval in US
26 Oct 2021 //
FDA
MSF demands newest COVID-19 treatment recommended by WHO accessible to all
27 Sep 2021 //
EXPRESS PHARMA
Pharmac funds tocilizumab to treat cases of COVID-19
16 Sep 2021 //
NZDOCTOR
TGA acts fast to stop arthritis drug running out amid COVID-driven shortage
08 Sep 2021 //
SMH
Hetero To Debut Biosimilar Actemra, Giving India Grasp On Supplies Security
08 Sep 2021 //
SCRIP
Biosimilar candidate of Fresenius shows positive results in 2 clinical trials
07 Sep 2021 //
PRESS RELEASE
India`s Hetero gets emergency use nod to make Roche`s COVID-19 drug
07 Sep 2021 //
REUTERS
New Zealand’s tocilizumab supply to be paused
04 Sep 2021 //
SCOOP
Advice on the use of tocilizumab i.v. vials post expiry date
30 Aug 2021 //
TGA
